cortisporin-tc- colistin sulfate, neomycin sulfate, thonzonium bromide, and hydrocortisone acetate suspension
physicians total care, inc. - colistin sulfate (unii: wp15dxu577) (colistin - unii:z67x93hjg1), neomycin sulfate (unii: 057y626693) (neomycin - unii:i16qd7x297), thonzonium bromide (unii: ji2b19cr0r) (thonzonium bromide - unii:ji2b19cr0r), hydrocortisone acetate (unii: 3x7931po74) (hydrocortisone - unii:wi4x0x7bpj) - colistin 3 mg in 1 ml - cortisporin® -tc otic suspension is indicated for the treatment of superficial bacterial infections of the external auditory canal, caused by organisms susceptible to the action of the antibiotics; and for the treatment of infections of mastoidectomy and fenestration cavities, caused by organisms susceptible to the antibiotics. this product is contraindicated in those individuals who have shown hypersensitivity to any of its components. this product should not be used if the external auditory canal disorder is suspected or known to be due to cutaneous viral infection (e.g., herpes simplex virus or varicella zoster virus).
coly-mycin s- colistin sulfate, neomycin sulfate, thonzonium bromide and hydrocortisone acetate suspension
endo pharmaceuticals inc. - colistin sulfate (unii: wp15dxu577) (colistin - unii:z67x93hjg1), neomycin sulfate (unii: 057y626693) (neomycin - unii:i16qd7x297), thonzonium bromide (unii: ji2b19cr0r) (thonzonium - unii:z05ze98fv8), hydrocortisone acetate (unii: 3x7931po74) (hydrocortisone - unii:wi4x0x7bpj) - colistin 3 mg in 1 ml - coly-mycin® s otic is indicated for the treatment of superficial bacterial infections of the external auditory canal, caused by organisms susceptible to the action of the antibiotics; and for the treatment of infections of mastoidectomy and fenestration cavities, caused by organisms susceptible to the antibiotics. this product is contraindicated in those individuals who have shown hypersensitivity to any of its components. this product should not be used if the external auditory canal disorder is suspected or known to be due to cutaneous viral infection (e.g., herpes simplex virus or varicella zoster virus).
hospira vincristine sulfate 1 mg/1ml injection usp
hospira australia pty ltd - vincristine sulfate, quantity: 1 mg/ml - injection - excipient ingredients: mannitol; water for injections; sulfuric acid; sodium hydroxide - vincristine sulfate is indicated in the treatment of acute leukemia. it has also been used in combination with other antineoplastic drugs in hodgkin's disease, soft-tissue sarcoma, bony-tissue sarcoma, sarcomas of specialized structures, breast cancer, small cell cancer of the lung, cancer of uterine cervix, malignant melanoma, colorectal cancer, non-hodgkin's lymphoma, and wilm's tumor.
marqibo- vincristine sulfate
talon therapeutics, inc. - vincristine sulfate (unii: t5iro3534a) (vincristine - unii:5j49q6b70f) - vincristine sulfate 5 mg in 5 ml - marqibo® is indicated for the treatment of adult patients with philadelphia chromosome-negative (ph-) acute lymphoblastic leukemia (all) in second or greater relapse or whose disease has progressed following two or more anti-leukemia therapies. this indication is based on overall response rate. clinical benefit such as improvement in overall survival has not been verified. marqibo is contraindicated in patients with demyelinating conditions including charcot-marie-tooth syndrome. marqibo is contraindicated in patients with hypersensitivity to vincristine sulfate or any of the other components of marqibo (vincristine sulfate liposome injection). marqibo is contraindicated for intrathecal administration. pregnancy category d [see warnings and precautions (5.9) ] based on its mechanism of action and findings from animal studies, marqibo can cause fetal harm when administered to pregnant women. if this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be
vincasar pfs- vincristine sulfate injection, solution
teva parenteral medicines, inc. - vincristine sulfate (unii: t5iro3534a) (vincristine - unii:5j49q6b70f) - vincristine sulfate 1 mg in 1 ml - vincasar pfs is indicated in acute leukemia. vincasar pfs has also been shown to be useful in combination with other oncolytic agents in hodgkin’s disease, non-hodgkin’s malignant lymphomas, rhabdomyosarcoma, neuroblastoma, and wilms’ tumor. patients with the demyelinating form of charcot-marie-tooth syndrome should not be given vincasar pfs. careful attention should be given to those conditions listed under warnings and precautions .
vincristine 1mg/1ml solution for injection vials
pfizer ltd - vincristine sulfate - solution for injection - 1mg/1ml
vincristine 2mg/2ml solution for injection vials
pfizer ltd - vincristine sulfate - solution for injection - 1mg/1ml
vincristine 5mg/5ml solution for injection vials
pfizer ltd - vincristine sulfate - solution for injection - 1mg/1ml
vincristine sulphate 1 micromol solution for inj/inf
hospira uk limited - vincristine sulfate - solution for inj/inf - 1 micromol - vinca alkaloids and analogues
dbl vincristine sulfate 2mg/2ml injection vial
pfizer australia pty ltd - vincristine sulfate, quantity: 1 mg/ml - injection, solution - excipient ingredients: sulfuric acid; mannitol; water for injections; sodium hydroxide - vincristine sulfate is indicated in acute leukaemia - current practices of cancer chemotherapy involve the simultaneous use of several agents. for enhanced therapeutic effect without additive toxicity, agents with different dose-limiting clinical toxicities and different mechanisms of action are generally selected. it is rarely possible to achieve equally good results with single agent treatment. thus vincristine sulfate is often chosen as part of polychemotherapy because of its unique clinical toxicity (neuropathy). see dosage and administration for possible increased toxicity when used in combination therapy. it has been shown to be useful in combination with other oncolytic agents in hodgkin's disease, non-hodgkin's malignant lymphomas (lymphocytic, mixed-cell, histiocytic, undifferentiated, nodular and diffuse types), rhabdomyosarcoma, neuroblastoma, wilm's tumour, osteogenic sarcoma, mycosis fungoides, ewing's sarcoma, carcinoma of the uterine cervix, breast cancer, malignant melanoma, oat-cell carcinoma